Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.99 USD | +3.37% | -2.92% | +30.82% |
Sales 2024 * | 68.9M 5.52B | Sales 2025 * | 102M 8.14B | Capitalization | 208M 16.67B |
---|---|---|---|---|---|
Net income 2024 * | -37M -2.96B | Net income 2025 * | -20M -1.6B | EV / Sales 2024 * | 3.02 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.05 x |
P/E ratio 2024 * |
-5.99
x | P/E ratio 2025 * |
-14.2
x | Employees | 100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.1% |
Latest transcript on G1 Therapeutics, Inc.
1 day | +3.37% | ||
1 week | -2.92% | ||
Current month | -7.64% | ||
1 month | -6.99% | ||
3 months | -2.21% | ||
6 months | +175.17% | ||
Current year | +30.82% |
Managers | Title | Age | Since |
---|---|---|---|
Jack Bailey
CEO | Chief Executive Officer | 59 | 11/03/20 |
John Umstead
DFI | Director of Finance/CFO | - | 31/12/17 |
Rajesh K. Malik
CTO | Chief Tech/Sci/R&D Officer | 65 | 30/06/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Muir
BRD | Director/Board Member | 65 | 31/08/15 |
Cynthia Flowers
BRD | Director/Board Member | 64 | 06/06/18 |
Norman Sharpless
FOU | Founder | 57 | 18/05/08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.01% | 509 M€ | -.--% | ||
0.01% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 3.99 | +3.37% | 441,518 |
25/04/24 | 3.86 | -3.26% | 538,433 |
24/04/24 | 3.99 | -4.77% | 343,841 |
23/04/24 | 4.19 | +2.20% | 354,923 |
22/04/24 | 4.1 | -0.24% | 488,179 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.82% | 208M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- GTHX Stock